Dr El-Khoueiry on Regorafenib/Pembrolizumab in Advanced HCC After Prior Anti–PD-1/L1 Therapy

Anthony B. El-Khoueiry, MD, on data for regorafenib plus pembrolizumab in pretreated advanced hepatocellular carcinoma.

Anthony B. El-Khoueiry, MD, associate director, clinical research, University of Southern California (USC) Norris Comprehensive Cancer Center, associate professor, clinical medicine, the Keck School of Medicine of USC, discusses findings from a phase 2 trial (NCT04696055) evaluating regorafenib (Stivarga) plus pembrolizumab (Keytruda) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on 1 prior immune checkpoint inhibitor–containing regimen.

Cohort 1 included patients who received prior treatment with atezolizumab (Tecentriq) plus bevacizumab (Avastin), and cohort 2 featured patients who were given any other immune-checkpoint inhibitor–based regimen, either as a single agent or as part of a combination. Patients in both cohorts received 90 mg of oral regorafenib per day for 3 weeks on and 1 week off plus 400 mg of intravenous pembrolizumab once every 6 weeks.

Regarding the trial’s primary end point of overall response rate (ORR), the ORR in cohort 1 (n = 68) was 5.9% (95% CI, 1.6%-14.4%) with a disease control rate (DCR) of 54.4% (95% CI, 41.9%-66.5%). In Cohort 2 (n = 27), the ORR was 11.1% (95% CI, 2.4%-29.2%) with a DCR of 74.1% (95% CI, 53.7%-88.9%). Notably, the study fell short of reaching its primary end point, as investigators anticipated an ORR of at least 35% to demonstrate superiority over the historical ORR of 20% in this setting, El-Khoueiry says.

El-Khoueiry notes that although patients in cohort 2 appeared to have better outcomes, this could be attributed to the more favorable disease characteristics of the patients in this group, including more patients with an ECOG performance status of 0 and Barcelona clinic liver cancer stage B disease, and fewer instances of macrovascular invasion or extrahepatic spread. El-Khoueiry explains that the study was not designed for a direct comparison between the cohorts.

Regarding the exploratory end point of progression-free survival (PFS), the median PFS was 2.8 months (95% CI, 2.4-3.9) in cohort 1 and 4.2 months (95% CI, 2.9-6.8) in cohort 2. The median overall survival was not evaluable in either cohort.

Related Videos
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD